Michele E. Paessler, DO

Michele E. Paessler, DO
Michele E. Paessler, DO, is division chief of Hematopathology Laboratory, medical director of Clinical Immunology Laboratory, and an attending hematopathologist at CHOP.

Areas of Expertise: Flow cytometry, Hematopathology
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

Education and Training

Medical School

DO - Philadelphia College of Osteopathic Medicine, Philadelphia, PA

Internship

Medicine - PCOM/Allegheny University Hospital, Philadelphia, PA

Residency

Pathology and Laboratory Medicine - University of Pennsylvania Medical Center, Philadelphia, PA

Fellowship

Molecular Pathology - University of Pennsylvania Medical Center, Philadelphia, PA
Hematopathology - University of Pennsylvania Medical Center, Philadelphia, PA
Molecular Genetic Pathology - University of Pennsylvania Medical Center, Philadelphia, PA

Board Certification

American Board of Pathology/Clinical Pathology
American Board of Pathology/Hematology
American Board of Pathology/Molecular Genetics

Titles and Academic Titles

Attending Hematopathologist

Division Chief, Hematopathology

Medical Director, Clinical Immunology Laboratory

Departments and Services

Publications

Papers

2013

Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Canna SW, Wrobel J, Chu N, Kreiger PA, Paessler M, Behrens EM. Arthritis Rheum. 2013 Jul;65(7):1764-75.

2011

Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Rothman JA, Das R, Teachey DT, Paessler ME, Nichols KE. Pediatr Blood Cancer. 2011 Dec 15;57(7):1239-43. doi: 10.1002/pbc.23226.

Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, Kambayashi T, Koretzky GA. J Clin Invest. 2011 Jun;121(6):2264-77.

Not all hemophagocytes are created equally: appreciating the heterogeneity of the hemophagocytic syndromes. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, Kambayashi T, Koretzky GA. J Clin Invest. 2011 Jun;121(6):2264-77.

2007

Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. J Pediatr Hematol Oncol. 2007 Aug;29(8):569-73.